This focused symposium brings together global experts in esophageal cancer to explore the evolving role of biomarkers and precision medicine in the early detection, diagnosis, and management of esophageal adenocarcinoma (EAC). Moderated by Dr. Daniela Molena of Memorial Sloan Kettering Cancer Center, the session highlights both foundational knowledge and the latest clinical advances.

The symposium opens with an overview of the clinical importance of precision diagnostics in EAC, followed by a pathologist from MSK who will delve into the histopathological progression from Barrett’s esophagus to EAC. This presentation highlights the biological basis for biomarker development by illustrating key tissue-level changes during disease progression.

Professor Hugh Barr from Gloucestershire NHS Trust will then present findings from the pivotal BOSS trial, critically evaluating current Barrett’s surveillance strategies and their limitations. His talk sets the stage for the need to evolve beyond traditional endoscopic monitoring and toward more targeted diagnostic tools.

Dr. Richard Lipscombe of Proteomics International will present clinical data on biomarker validation, presenting results from the PromarkerEso study. This talk provides evidence supporting blood-based biomarkers as a non-invasive method to stratify patients at risk for EAC.

Professor Krish Ragunath from Royal Perth Hospital and Curtin University will present a comparative analysis of diagnostic strategies in EAC, highlighting the strengths and limitations of current technologies, diagnostic devices, and in vitro diagnostics (IVDs). He will also explore future directions for integrating precision diagnostics into clinical practice, including their role in monitoring patients following EAC therapy.

The symposium concludes with a panel discussion, led by Dr. Molena, offering insights into real world implementation challenges, the future of biomarker-driven care, and opportunities for audience engagement. This session aims to catalyze new thinking in EAC detection and personalize care for patients at risk.